|
|||||
|
|
Correction to: Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model |
|
| Authors: | Prathipati Pavan Kumar Mandal Subhra Pon Gregory Vivekanandan Renuga Destache Christopher J. |
| Affiliation: | 1.Department of Electrical, Computer and Biomedical Engineering, Università degli Studi di Pavia, Pavia, Italy ;3.Janssen R&D, San Diego, California, USA ;4.Janssen R&D, Beerse, Belgium ;5.German CLL Study Group, University Hospital of Cologne, Cologne, Germany ;6.Dokuz Eylul University, Izmir, Turkey ;7.Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada ;8.Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA ;9.H?pital Haut-Lévêque, Bordeaux, Pessac, France ;10.Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain ;11.Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel Aviv, Tel Aviv, Israel ;12.Derriford Hospital, Plymouth, UK ;13.Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia ;14.John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA ;15.University of Kansas Medical Center, Kansas City, Kansas, USA ;16.Raritan, New Jersey, USA ;17.Janssen R&D, High Wycombe, UK ;18.Global Clinical Pharmacology, Quantitative Sciences, Janssen-Cilag SpA, Via Michelangelo Buonarroti 23, 20093, Cologno Monzese, MI, Italy ; |
| Abstract: | Pharmaceutical Research - In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |